2026-09-18T23:56:49Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/1045352022-01-13T07:54:52Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023

Robert S. Langer. Grislain, Jacques-Henry Sloan School of Management. Sloan School of Management 2016-09-30T19:34:23Z 2016-09-30T19:34:23Z 2016 2016 http://hdl.handle.net/1721.1/104535 958300137 Thesis: S.M. in Management Studies, Massachusetts Institute of Technology, Sloan School of Management, 2016. Cataloged from PDF version of thesis. Includes bibliographical references (page 92). The Biotechnology investment sector has been booming over the last ten years delivering substantial financial returns for public and private investors and most VC firms have been raising and deploying a lot of capital into fast-growing Biotechnology companies. However, it may seem paradoxical that the Biotechnology industry attracts increasingly more Venture Capital and Public funding whereas it is one of the riskiest and volatile sectors and most early-stage companies do not generate revenues for years and have large financial needs to cover expensive clinical trials. My research will focus on Biotechnology investments in the US and will cover the value chain of a Venture Capital firm with a competitive analysis, a detailed review of current funding trends, a performance review analysis and a study to explain why Boston has become the n°1 cluster for Biotechnology in the US. The study also includes feedbacks from 25 interviews conducted with Founders and CEOs of Biotechnology companies, Life Sciences experts, Scientists and Venture Capital investors. by Jacques-Henry Grislain. S.M. in Management Studies 94 pages eng Massachusetts Institute of Technology M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 Sloan School of Management. The venture capital in the biotechnology industry Thesis application/pdf Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="7b31aa13-7713-45dc-9aeb-d5b75ebec1cf"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>The venture capital in the biotechnology industry</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2016</PublicationDate> <Authors> <Author> <DisplayName>Grislain, Jacques-Henry</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Sloan School of Management.</Keyword> <Abstract>The Biotechnology investment sector has been booming over the last ten years delivering substantial financial returns for public and private investors and most VC firms have been raising and deploying a lot of capital into fast-growing Biotechnology companies. However, it may seem paradoxical that the Biotechnology industry attracts increasingly more Venture Capital and Public funding whereas it is one of the riskiest and volatile sectors and most early-stage companies do not generate revenues for years and have large financial needs to cover expensive clinical trials. My research will focus on Biotechnology investments in the US and will cover the value chain of a Venture Capital firm with a competitive analysis, a detailed review of current funding trends, a performance review analysis and a study to explain why Boston has become the n°1 cluster for Biotechnology in the US. The study also includes feedbacks from 25 interviews conducted with Founders and CEOs of Biotechnology companies, Life Sciences experts, Scientists and Venture Capital investors.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>